The development of antibodies targeting chemokine receptors or chemokines that mediate neutrophil recruitment like Cxcr1/2-Cxcl8 and Cxcr4/ Ackr3-Cxcl12 could be used as an alternative anti-inflammatory and anti-oncogenic treatment to modulate neutrophil recruitment to inflammatory foci and tumor-initiating niches, respectively (75). Here, CXCL12 is linked to neoplasm.